<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03575650</url>
  </required_header>
  <id_info>
    <org_study_id>2018-06</org_study_id>
    <nct_id>NCT03575650</nct_id>
  </id_info>
  <brief_title>Early Detection of Imaging-derived Subclinical Cardiac Injuries</brief_title>
  <acronym>EMIRA</acronym>
  <official_title>Early Detection of Imaging-derived Subclinical Cardiac Injuries After Radiotherapy and Chemotherapy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Utrecht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer (BC) radiotherapy leads to incidental cardiac irradiation, resulting in an&#xD;
      increased risk of various major cardiac events (MCEs). In addition, recent studies indicate&#xD;
      that for the treatment of BC, the addition of chemotherapy further enhances the risk of MCEs.&#xD;
      Information regarding morphological and functional early subclinical cardiac injuries (ESCIs)&#xD;
      induced by chemotherapy and radiotherapy that develop into MCEs is largely lacking in&#xD;
      scientific literature. This information is essential towards the development of primary and&#xD;
      secondary preventive strategies. The EMIRA prospective cohort has as main objective to&#xD;
      identify morphological and functional ESCIs in BC patients treated with adjuvant radiotherapy&#xD;
      and chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EMIRA is a single centre prospective observational cohort study performed in the UMCG. The&#xD;
      study includes breast cancer patients that underwent primary surgery, either by mastectomy or&#xD;
      breast conserving surgery, who are treated with adjuvant radiotherapy and chemotherapy as&#xD;
      part of routine clinical care. The patient follow up time continues for 2 years after&#xD;
      radiotherapy to identify early subclinical cardiac injuries (ESCIs), using repeat&#xD;
      echocardiography (cECHO), cardiac MRI (cMRI) scans and cardiac CT (cCT) scans. The images are&#xD;
      acquired prior to chemotherapy and/or radiotherapy (depending on the sequence of adjuvant&#xD;
      treatment), and at 6 and 24 months after radiotherapy The first primary aim of this project&#xD;
      is to detect ESCIs that are considered risk factors for clinically apparent major cardiac&#xD;
      events in breast cancer patients treated with radiotherapy and chemotherapy. The second is to&#xD;
      use this information to develop prediction models describing the relationship between the&#xD;
      radiation dose to cardiac substructures and ESCIs.&#xD;
&#xD;
      In detail, the investigators aim to:&#xD;
&#xD;
        1. identify longitudinal morphological and functional ESCIs using echocardiography, cardiac&#xD;
           MRI and cardiac CT before and after BC treatment;&#xD;
&#xD;
        2. determine the relationship between 3D-dose distributions to cardiac substructures and&#xD;
           ESCI;&#xD;
&#xD;
        3. establish the effect of chemotherapy on the dose-effect relationship between radiation&#xD;
           dose and ESCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">September 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 4, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricle Global Longitudinal Strain (LV-GLS) assessed by echocardiography</measure>
    <time_frame>6 and 24 months after radiotherapy with reference to baseline</time_frame>
    <description>Increasement in left ventricle Global Longitudinal Strain (GLS) of at least 5%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in myocardial function assessed by echocardiography</measure>
    <time_frame>6 and 24 after completion of radiotherapy with reference to baseline</time_frame>
    <description>Increasement of segmental strain measurements (unit of measures:%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomical changes in coronary arteries by cardiac CT</measure>
    <time_frame>6 and 24 after completion of radiotherapy with reference to baseline</time_frame>
    <description>Increase in the number of coronary segments containing any plaque/stenosis, or increase in calcium score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial tissue abnormalities assessed by cardiac MRI</measure>
    <time_frame>6 and 24 after completion of radiotherapy with reference to baseline</time_frame>
    <description>Increase of the native mean myocardial T1 mapping value assessed by cardiac MRI</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Cardiac imaging modalities</arm_group_label>
    <description>Repeat echocardiography (cECHO), cardiac MRI (cMRI) scans and cardiac CT (cCT) scans will be performed to evaluate myocardial dysfunction and deformation; myocardium inclusing tissue abnormalities, cardiac morphology and function and; coronary artery lesions and coronary artery calcium score.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac imaging modalities</intervention_name>
    <description>Repeat cardiac echocardiographies, MRI-scans and CT-scans for early subclinical biomarker assessments in breast cancer patients treated with chemotherapy and radiotherapy</description>
    <arm_group_label>Cardiac imaging modalities</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients with unilateral BC aged 40-75 years who underwent primary surgery, either&#xD;
        by mastectomy or by breast conserving surgery, who are treated with adjuvant radiotherapy&#xD;
        and chemotherapy as part of routine clinical care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female unilateral BC patients&#xD;
&#xD;
          2. Primary breast conserving surgery or mastectomy for stage I-III invasive&#xD;
             adenocarcinoma of the breast or ductal carcinoma in situ (DCIS)&#xD;
&#xD;
          3. Age between 40-70 years at time of chemotherapy/radiotherapy&#xD;
&#xD;
          4. WHO performance status 0-1&#xD;
&#xD;
          5. Planned radiotherapy to the breast/chest wall with or without the lymph node areas&#xD;
&#xD;
          6. Radiotherapy based on planning CT-scan, using either 3D CRT, (partial) IMRT or&#xD;
             (partial) VMAT/RapidArc with or without deep inspiration breath-hold&#xD;
&#xD;
          7. Adjuvant systemic chemotherapy (before or after radiotherapy)&#xD;
&#xD;
          8. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male BC patients&#xD;
&#xD;
          2. M1 disease (metastatic BC)&#xD;
&#xD;
          3. Previous thoracic or mediastinal radiation&#xD;
&#xD;
          4. Neo-adjuvant chemotherapy not allowed&#xD;
&#xD;
          5. Targeted HER2 therapy not allowed&#xD;
&#xD;
          6. Medical history of coronary artery disease and/or myocardial infarction and/or atrial&#xD;
             fibrillation&#xD;
&#xD;
          7. Contraindications to injection of iodinated contrast such as allergy or renal failure&#xD;
&#xD;
          8. Pregnancy or lactation&#xD;
&#xD;
          9. Atrial fibrillation detected during electrocardiogram before chemotherapy/radiotherapy&#xD;
&#xD;
         10. Abnormal echocardiography before chemotherapy/radiotherapy defined as: LVEF &lt;50%,&#xD;
             longitudinal strain &lt;-16%, longitudinal strain rate &lt;-1%, and/or abnormal wall motion&#xD;
&#xD;
         11. Presence of myocardial infarction detected during cMRI before&#xD;
             chemotherapy/radiotherapy&#xD;
&#xD;
         12. cMRI or cCT results before chemotherapy/radiotherapy requiring revascularisation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Langendijk, Prof.Dr</last_name>
    <role>Study Chair</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Crijns, MD, PhD</last_name>
    <phone>+31503616161</phone>
    <email>a.p.g.crijns@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Crijns, MD PhD</last_name>
      <phone>+31-652724432</phone>
      <email>a.p.g.crijns@umcg.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>A.P.G. Crijns</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

